These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 7527984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR, Platz KP, Berg T, Fukomoto T, Guckelberger O, Neuhaus R, Bechstein WO, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract] [Full Text] [Related]

  • 5. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation.
    Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1468-9. PubMed ID: 9636596
    [No Abstract] [Full Text] [Related]

  • 6. Optimal immunosuppressive clinical regimen in liver transplantation.
    Farges O, Samuel D, Bismuth H.
    Transplant Proc; 1994 Oct; 26(5):2676-8. PubMed ID: 7940838
    [No Abstract] [Full Text] [Related]

  • 7. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP, Tullius SG, Mueller AR, Schumacher G, Nüssler N, Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES, Perdrizet GA, So S, Jendrisak MD, White HM, Marsh JW.
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 11. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
    [Abstract] [Full Text] [Related]

  • 12. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH, Porayko MK, Wahlstrom HE, Gores GJ, Kamath PS, Hay JE, Krom RA.
    Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neurotoxicity of FK 506 in liver transplant recipients.
    Frank B, Perdrizet GA, White HM, Marsh JW, Lemann W, Woodle ES.
    Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
    [No Abstract] [Full Text] [Related]

  • 15. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
    Elkashab M, Reizig M, Greig PD, Cameron R, Phillips MJ, Chung S, Cattral M, Levy G.
    Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
    [No Abstract] [Full Text] [Related]

  • 16. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.
    Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H.
    Hepatology; 1996 Feb; 23(2):240-8. PubMed ID: 8591847
    [Abstract] [Full Text] [Related]

  • 17. Reversal of chronic rejection after treatment failure with FK506 and RS61443.
    Roberts JP, Lake JR, Hebert M, Nikolai B, Ascher NL, Ferrell LD.
    Transplantation; 1993 Oct; 56(4):1021-3. PubMed ID: 7692634
    [No Abstract] [Full Text] [Related]

  • 18. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hepatic allograft rejection under quadruple immunosuppressive regimen with cyclosporine A in liver transplantation: incidence of viral and fungal infection.
    Fabregat J, Fradera R, Figueras J, Rafecas A, Torras J, Martinez LaCasa J, Baliellas C, Casais L, Jaurrieta E.
    Transplant Proc; 1994 Oct; 26(5):2697-9. PubMed ID: 7940845
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.